Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to look at the effects (good or bad) that Atrasentan given
alone and Atrasentan given with Zometa has on levels of bone formation and bone destruction
in men with prostate cancer that has spread to the bones.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Abbott Brigham and Women's Hospital Dana-Farber Cancer Institute